Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
unknownnot_applicable

Leuven Interactive Scheme for hearingTraining Evaluation, and Audiological Rehabilitation

NCT04063748
completednot_applicable

Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation

NCT02991781
unknownnot_applicable

Cognitive Reserve and Second Language Acquisition

NCT03638882
completedphase_2

Acute Effects of Exercise in Smokers With Schizophrenia

NCT01635075

Clinical Trials (4)

Showing 4 of 4 trials
NCT04063748Not Applicable

Leuven Interactive Scheme for hearingTraining Evaluation, and Audiological Rehabilitation

Unknown
NCT02991781Not Applicable

Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation

Completed
NCT03638882Not Applicable

Cognitive Reserve and Second Language Acquisition

Unknown
NCT01635075Phase 2

Acute Effects of Exercise in Smokers With Schizophrenia

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4